Posted in | Nanomedicine | Nanobusiness

Tekmira Receives Patents for Mitigation of Immune Stimulation and Lipid Nanoparticle Formulations

Tekmira Pharmaceuticals, a company specializing in RNA interference (RNAi) therapeutics, has declared that its intellectual property portfolio has been expanded by the issuance of two key patents by the United States Patent & Trademark Office (USPTO).

In these two patents, U.S. Patent No. 8,058,069 covers Tekmira Pharmaceuticals’ lipid nanoparticle delivery technology, while the U.S. Patent No. 8,101,741 covers the chemical change of siRNA to alleviate immune stimulation.

By issuing the U.S. Patent No. 8,058,069, the USPTO has granted claims related to specific ratios of lipids utilized in Tekmira Pharmaceuticals’ lipid nanoparticle formulations, which have demonstrated to deliver enhanced tolerability and improved drug activity of the in vivo formulations, thus increasing the therapeutic index substantially when compared to other compositions.

By issuing the U.S. Patent No. 8,101,741, the USPTO has granted claims related to the chemical change of siRNA sequences to stop immune stimulation. This patent is based on the research conducted by Tekmira Pharmaceuticals researchers about the activation of the innate immune system using nucleic acids such as siRNA.

According to Mark J. Murray, President and Chief Executive Officer at Tekmira Pharmaceuticals, the company believes that all lipid nanoparticle-based RNAi therapeutic drugs currently under clinical development will come under the U.S. Patent No. 8,058,069. The company continues to develop and protect all features of its proprietary lipid nanoparticle technology.

Murray further said that the U.S. Patent No. 8,101,741 is the latest addition to the company’s expanding portfolio of intellectual property related to techniques of alleviating siRNA immune activation through chemical change.

Source: http://www.tekmirapharm.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 12). Tekmira Receives Patents for Mitigation of Immune Stimulation and Lipid Nanoparticle Formulations. AZoNano. Retrieved on September 29, 2020 from https://www.azonano.com/news.aspx?newsID=24250.

  • MLA

    Chai, Cameron. "Tekmira Receives Patents for Mitigation of Immune Stimulation and Lipid Nanoparticle Formulations". AZoNano. 29 September 2020. <https://www.azonano.com/news.aspx?newsID=24250>.

  • Chicago

    Chai, Cameron. "Tekmira Receives Patents for Mitigation of Immune Stimulation and Lipid Nanoparticle Formulations". AZoNano. https://www.azonano.com/news.aspx?newsID=24250. (accessed September 29, 2020).

  • Harvard

    Chai, Cameron. 2019. Tekmira Receives Patents for Mitigation of Immune Stimulation and Lipid Nanoparticle Formulations. AZoNano, viewed 29 September 2020, https://www.azonano.com/news.aspx?newsID=24250.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit